Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial

authors

• Carpentier Alexandre
• Stupp Roger
• Sonabend Adam
• Dufour Henry
• Chinot Olivier
• Mathon Bertrand
• Ducray François
• Guyotat Jacques
• Baize Nathalie
• Menei Philippe
• de Groot John
• Weinberg Jeffrey
• Liu Benjamin
• Guemas Eric
• Desseaux Carole
• Schmitt Charlotte
• Bouchoux Guillaume
• Canney Michael
• Idbaih Ahmed

document type

abstract

Here, the results of a phase 1/2 single-arm trial (NCT03744026) assessing the safety and efficacy of blood-brain barrier (BBB) disruption with an implantable ultrasound system in recurrent glioblastoma patients receiving carboplatin are reported. A nine-emitter ultrasound implant was placed at the end of tumor resection replacing the bone flap. After surgery, activation to disrupt the BBB was performed every four weeks either before or after carboplatin infusion. The primary objective of the Phase 1 was to evaluate the safety of escalating numbers of ultrasound emitters using a standard 3 + 3 dose escalation. The primary objective of the Phase 2 was to evaluate the efficacy of BBB opening using magnetic resonance imaging (MRI). The secondary objectives included safety and clinical efficacy. Thirty-three patients received a total of 90 monthly sonications with carboplatin administration and up to nine emitters activated without observed DLT. Grade 3 procedure-related adverse events consisted of pre syncope ( n = 3), fatigue ( n = 1), wound infection ( n = 2), and pain at time of device connection ( n = 7). BBB opening endpoint was met with 90% of emitters showing BBB disruption on MRI after sonication. In the 12 patients who received carboplatin just prior to sonication, the progression-free survival was 3.1 months, the 1-year overall survival rate was 58% and median overall survival was 14.0 months from surgery.

more information